| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
The Private Diagnostic Clinic (PDC) is the physician practice of Duke Health. It is one of the first and the largest academic multi-specialty group practices in the United States. The PDC is a member-led organization more than 1,600 members, and is governed by a Board of Managers. As a professional limited liability company (PLLC), the PDC owns and operates primary care and specialty care clinics in central and eastern North Carolina, as well as the Triad. Through a diverse and integrated network of providers, patients have convenient, accessible and high quality primary and specialty care close to home. In addition to patient care, PDC members conduct cutting-edge research and train the future health care workforce as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke`s clinical, research and academic missions.
Camden County Health Service Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Camden County Health Service Center is based in Blackwood, NJ. You can find more information on Camden County Health Service Center at www.cchsc.com
The Friedman Marketing Group is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cypress Creek EMS is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.